MAXALT 10 mg tablete Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

maxalt 10 mg tablete

merck sharp & dohme, d.o.o. - rizatriptan - tableta - rizatriptan 10 mg / 1 tableta - rizatriptan

MAXALT 5 mg peroralni liofilizat Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

maxalt 5 mg peroralni liofilizat

merck sharp & dohme, d.o.o. - rizatriptan - peroralni liofilizat - rizatriptan 5 mg / 1 prašek - rizatriptan

MAXALT 5 mg tablete Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

maxalt 5 mg tablete

merck sharp & dohme, d.o.o. - rizatriptan - tableta - rizatriptan 5 mg / 1 tableta - rizatriptan

Amoksiklav 125 mg/31,25 mg v 5 ml prašek za peroralno suspenzijo za otroke Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amoksiklav 125 mg/31,25 mg v 5 ml prašek za peroralno suspenzijo za otroke

lek d.d. - amoksicilin; klavulanska kislina - prašek za peroralno suspenzijo - amoksicilin 25 mg / 1 ml  klavulanska kislina6,25 mg / 1 ml; klavulanska kislina 6,25 mg / 1 ml - amoksicilin in zaviralec laktamaz beta

Rizatriptan Lek 10 mg orodisperzibilne tablete Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

rizatriptan lek 10 mg orodisperzibilne tablete

lek d.d. - rizatriptan - orodisperzibilna tableta - rizatriptan 10 mg / 1 tableta - rizatriptan

Valcyte 50 mg/ml prašek za peroralno raztopino Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

valcyte 50 mg/ml prašek za peroralno raztopino

roche d.o.o. - valganciklovir - prašek za peroralno raztopino - valganciklovir 4,99 g / 1 vsebnik - valganciklovir

Amoksiklav 250 mg/62,5 mg v 5 ml prašek za peroralno suspenzijo za otroke Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

amoksiklav 250 mg/62,5 mg v 5 ml prašek za peroralno suspenzijo za otroke

lek d.d. - amoksicilin; klavulanska kislina - prašek za peroralno suspenzijo - amoksicilin 50 mg / 1 ml  klavulanska kislina12,5 mg / 1 ml; klavulanska kislina 12,5 mg / 1 ml - amoksicilin in zaviralec laktamaz beta

Rizatriptan Lek 5 mg orodisperzibilne tablete Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

rizatriptan lek 5 mg orodisperzibilne tablete

lek d.d. - rizatriptan - orodisperzibilna tableta - rizatriptan 5 mg / 1 tableta - rizatriptan

Imatinib Koanaa Evropská unie - slovinština - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

Ospamox 250 mg/5 ml prašek za peroralno suspenzijo Slovinsko - slovinština - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ospamox 250 mg/5 ml prašek za peroralno suspenzijo

lek d.d. - amoksicilin - prašek za peroralno suspenzijo - amoksicilin 50 mg / 1 ml - amoksicilin